Zobair Younossi, MD

Articles by Zobair Younossi, MD

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

ByNaoky Tsai, MD,Bruce Bacon, MD,Michael Curry, MD,Steven L. Flamm, MD,Scott Milligan, PhD,Nicole Wick, AS,Zobair Younossi, MD,Nezam Afdhal, MD

July 12th 2019

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

ByZobair Younossi, MD,Stuart C. Gordon, MD,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD,Rachel Beckerman, PhD

February 16th 2017

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Latest Updated Articles

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
Published: February 16th 2017 | Updated:
Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017
Published: July 12th 2019 | Updated:

Zobair Younossi, MD

Articles by Zobair Younossi, MD

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Latest Updated Articles

Trending on AJMC

Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets

Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc

Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes

Debunking Myths to Boost Clinical Trial Enrollment Diversity: Susan Vadaparampil, PhD, MPH

Trends in Acupuncture Billing by a Large Commercial Insurer